PMID- 29632725
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231105
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 7
IP  - 4
DP  - 2018
TI  - SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.
PG  - e1412030
LID - 10.1080/2162402X.2017.1412030 [doi]
LID - e1412030
AB  - Purpose: To investigate the immunoprevalence of SALL4-derived peptides in healthy 
      volunteers and cancer patients. Experimental Design: A multistep approach 
      including prediction algorithms was used to design in silico SALL4-derived 
      peptides theoretically able to bind on common HLA-DR and HLA-A/B molecules. The 
      presence of T-cell responses after a long term T-cell assay (28 days) against 
      SALL4 was monitored in 14 healthy donors and the presence of T-cell responses 
      after a short term T-cell assay (10 days) was monitored in 67 cancer patients 
      using IFN-gamma ELISPOT assay. A T-cell clone specific for the immunoprevalent A18 
      K-derived peptide was isolated, characterized and used as a tool to characterize 
      the natural processing of A18 K. Results: A SALL4 specific T-cell repertoire was 
      present in healthy donors (8/14) and cancer patients (29/67) after short term 
      T-cell assay. We further identified two immunoprevalant SALL4-derived peptides, 
      R18 A and A18 K, which bind MHC-class II. In parallel, an A18 K specific Th1 
      clone recognized monocyte derived Dendritic Cell (moDC) loaded with SALL4 
      containing cell lysate. The level of IFN-gamma secreted by specific T-cell clone was 
      greater in presence of moDC loaded with SALL4 containing cell lysate (49.23 +/- 
      14.02%) than with moDC alone (18.03 +/- 3.072%) (p = 0.0477) Conclusion: These 
      results show for the first time immunogenicity of SALL4 oncogenic protein-derived 
      peptides, especially A18 K and R18 A peptides and make them potential targets for 
      personalized medicine. Thus, SALL4 possess major characteristics of a tumor 
      antigen.
FAU - Kroemer, Marie
AU  - Kroemer M
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
AD  - Department of pharmacy, University hospital of Besancon, Besancon, France.
FAU - Spehner, Laurie
AU  - Spehner L
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
FAU - Mercier-Letondal, Patricia
AU  - Mercier-Letondal P
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
FAU - Boullerot, Laura
AU  - Boullerot L
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
FAU - Kim, Stefano
AU  - Kim S
AD  - Department of medical oncology, University Hospital of Besancon, Besancon, 
      France.
FAU - Jary, Marine
AU  - Jary M
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
AD  - Department of medical oncology, University Hospital of Besancon, Besancon, 
      France.
FAU - Galaine, Jeanne
AU  - Galaine J
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
FAU - Picard, Emilie
AU  - Picard E
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
FAU - Ferrand, Christophe
AU  - Ferrand C
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
FAU - Nguyen, Thierry
AU  - Nguyen T
AD  - Department of medical oncology, University Hospital of Besancon, Besancon, 
      France.
FAU - Larosa, Fabrice
AU  - Larosa F
AD  - Department of hematology, University Hospital of Besancon, Besancon, France.
FAU - Adotevi, Olivier
AU  - Adotevi O
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
AD  - Department of medical oncology, University Hospital of Besancon, Besancon, 
      France.
FAU - Godet, Yann
AU  - Godet Y
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
FAU - Borg, Christophe
AU  - Borg C
AD  - University of Bourgogne Franche-Comte (UBFC), INSERM, EFS BFC, UMR1098, 
      Interactions hote-greffon-tumeur - Ingenierie Cellulaire et Genique, Besancon, 
      France.
AD  - Department of medical oncology, University Hospital of Besancon, Besancon, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20180117
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC5889287
OTO - NOTNLM
OT  - Cancer
OT  - Immunotherapy
OT  - SALL4
OT  - T Lymphocytes
OT  - Tumor antigen
EDAT- 2018/04/11 06:00
MHDA- 2018/04/11 06:01
PMCR- 2019/01/17
CRDT- 2018/04/11 06:00
PHST- 2017/06/20 00:00 [received]
PHST- 2017/11/11 00:00 [revised]
PHST- 2017/11/26 00:00 [accepted]
PHST- 2018/04/11 06:00 [entrez]
PHST- 2018/04/11 06:00 [pubmed]
PHST- 2018/04/11 06:01 [medline]
PHST- 2019/01/17 00:00 [pmc-release]
AID - 1412030 [pii]
AID - 10.1080/2162402X.2017.1412030 [doi]
PST - epublish
SO  - Oncoimmunology. 2018 Jan 17;7(4):e1412030. doi: 10.1080/2162402X.2017.1412030. 
      eCollection 2018.